The use of NHSBT NCI products for therapeutic antibody development
Research type
Research Study
Full title
The use of non-clinical issue products from NHSBT for the development of antibody therapeutics in fibrotic disease
IRAS ID
354321
Contact name
Ralph Minter
Contact email
Sponsor organisation
Forth Therapeutics
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
The UK has seen a 4-fold increase in liver disease in the past 50 years and approximately 2 million people die worldwide annually. There are currently no approved anti-fibrotic therapies in liver fibrosis so new treatment options are desperately needed.
Forth Therapeutics is focused on developing therapeutics for the treatment of liver disease. We are developing antibodies to deplete specific liver cell types which contribute to fibrosis. The work being carried out in Cambridge, UK will characterise antibodies for their ability to deplete specific cell types in the liver, thereby improving liver function.
In particular we would like to use primary human immune cells from non-clinical issue products from NHSBT (e.g. leucocyte cones, whole blood) to test these antibodies and assess their function.
REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
25/YH/0035
Date of REC Opinion
14 Feb 2025
REC opinion
Favourable Opinion